ARL3 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung carcinoma cell line, engineered to disrupt the ARL3 gene. This polyclonal pool provides a heterogeneous loss-of-function model for studying ARL3-dependent processes without the selection of a single clonal isolate.
The parental A-549 cell line is a widely used model of lung adenocarcinoma, established from the carcinoma of a 58-year-old Caucasian male. These cells exhibit characteristics of type II alveolar epithelial cells and carry a KRAS G12S activating mutation, making them particularly relevant for studying oncogenic signaling cross-talk with ciliary and trafficking pathways.
ARL3 is a small GTPase that cycles between an active GTP-bound state and an inactive GDP-bound state, regulated by the exchange factor ARL13B and the GTPase-activating protein RP2. In its active form, ARL3 promotes the release of myristoylated cargo from the carrier protein UNC119, a critical step for ciliary targeting. Mutations in ARL3 are associated with ciliopathies such as Joubert syndrome and retinitis pigmentosa. ARL3 interacts with PDE6D, RP2, ARL13B, BART, and tubulin, and functions downstream of ARL13B to modulate transport within the primary cilium. Its activity is essential for Hedgehog signaling and proper ciliary protein composition, linking ARL3 to intraflagellar transport (IFT) complex dynamics and microtubule-based trafficking.
In A-549 lung adenocarcinoma cells, ARL3 disruption provides a unique tool to dissect the interplay between oncogenic KRAS signaling, ciliogenesis, and Hedgehog pathway activity. Primary cilia are increasingly recognized as modulators of cancer cell proliferation and drug sensitivity, and ARL3-dependent trafficking may influence the ciliary localization of receptors and effectors relevant to tumor progression. The polyclonal knockout population enables evaluation of how ARL3 loss affects cilia formation, morphology, and downstream signaling in a KRAS-mutant background, without clonal selection bias.
This polyclonal knockout population enables diverse functional studies: western blotting and RT-qPCR for ARL3 expression analysis, immunofluorescence with ciliary markers (acetylated tubulin, ARL13B) for ciliogenesis assays, and flow cytometry to assess ciliation frequency. It is suited for co-immunoprecipitation to map ARL3 interactors, migration and invasion assays, and Hedgehog reporter assays to probe signaling activity. Additionally, drug sensitivity screens can be performed to explore how ciliary dysfunction alters therapeutic response in lung cancer. For further information, contact Ascent Research.
